Pressure BioSciences, Inc.
PBIO · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.02 | 0.02 | 0.01 |
| FCF Yield | -41.47% | -31.29% | -32.56% | -69.74% |
| EV / EBITDA | -3.25 | -6.46 | -5.40 | -2.22 |
| Quality | ||||
| ROIC | 96.35% | 40.30% | 55.34% | 62.80% |
| Gross Margin | 40.43% | -16.46% | 52.94% | 52.25% |
| Cash Conversion Ratio | 0.11 | 0.28 | 0.24 | 0.31 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.41% | 12.31% | 3.42% | -20.81% |
| Free Cash Flow Growth | 29.01% | 9.87% | -2.18% | 23.08% |
| Safety | ||||
| Net Debt / EBITDA | -2.43 | -3.80 | -2.62 | -1.28 |
| Interest Coverage | -0.61 | -0.47 | -0.29 | -0.55 |
| Efficiency | ||||
| Inventory Turnover | 3.86 | 2.93 | 0.82 | 0.98 |
| Cash Conversion Cycle | -286.69 | 71.25 | 268.20 | -72.96 |